Page last updated: 2024-09-03

elacridar and Neoplasm Metastasis, Unknown Primary

elacridar has been researched along with Neoplasm Metastasis, Unknown Primary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beijnen, JH; Jewell, RC; Koopman, FJ; Malingré, MM; Paul, EM; Rosing, H; Schellens, JH; Ten Bokkel Huinink, WW	1

Trials

1 trial(s) available for elacridar and Neoplasm Metastasis, Unknown Primary

Article	Year
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. British journal of cancer, 2001, Jan-05, Volume: 84, Issue:1 Topics: Acridines; Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Tetrahydroisoquinolines	2001

Article

Year

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.

British journal of cancer, 2001, Jan-05, Volume: 84, Issue:1

Topics: Acridines; Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Tetrahydroisoquinolines

2001